Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2015
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
gptkb:A04AD12
|
| gptkbp:CASNumber |
552292-08-7
|
| gptkbp:chemicalFormula |
C25H26F6N2O2
|
| gptkbp:contraindication |
hypersensitivity to rolapitant
|
| gptkbp:drugClass |
NK1 receptor antagonist
|
| gptkbp:genericName |
rolapitant
|
| https://www.w3.org/2000/01/rdf-schema#label |
Varubi
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Tesaro
|
| gptkbp:molecularWeight |
500.48 g/mol
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
dizziness
neutropenia dyspepsia decreased appetite hiccups |
| gptkbp:usedFor |
chemotherapy-induced nausea and vomiting
prevention of nausea and vomiting |
| gptkbp:bfsParent |
gptkb:TESARO
gptkb:Tesaro |
| gptkbp:bfsLayer |
8
|